Bryan P Schneider

Trials

Studies that name Bryan P Schneider as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:12 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT06081517 · Evaluating Disparities in Precision Oncology

  Indiana University · recruiting · Metastatic Cancer, Advanced Cancer · principal investigator
• Ph2
  NCT04849364 · Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

  Bryan Schneider, MD · terminated · Breast Cancer, Triple Negative Breast Cancer · principal investigator
• Ph2
  NCT04001829 · Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

  ECOG-ACRIN Cancer Research Group · active not recruiting · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 · principal investigator
• N/A
  NCT02610426 · Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  National Cancer Institute (NCI) · recruiting · Breast Carcinoma · principal investigator
• N/A
  NCT02610413 · Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

  National Cancer Institute (NCI) · recruiting · Breast Carcinoma · principal investigator
• N/A
  NCT02610439 · Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

  National Cancer Institute (NCI) · recruiting · Breast Carcinoma, Neuropathy · principal investigator
• N/A
  NCT02587026 · Biorepository for Precision Genomics

  Indiana University · terminated · Neoplasms · principal investigator
• N/A
  NCT01156168 · Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab

  ECOG-ACRIN Cancer Research Group · completed · Breast Cancer · principal investigator
• N/A
  NCT00899418 · Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100

  Eastern Cooperative Oncology Group · completed · Breast Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Targeting HER2-low breast cancer with 17p loss
  R01CA203737 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2021 to 2023 · $524,740 awarded in 2023
  Same name and institution; not confirmed by an ID
• VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer
  R01CA155311 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2011 to 2013 · $303,371 awarded in 2013
  Same name and institution; not confirmed by an ID
• PILOT EVALUATION OF THE ROLE OF POLYMORPHISMS OF ANGIOGENESIS GENES IN BREAST
  M01RR000750 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2006 to 2008 · $9,734 awarded in 2008
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN NCORP Research Base
  UG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL, Lynne I. Wagner · fiscal years 2014 to 2026
  Named on NCT04001829
• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
  Named on NCT02610426, NCT02610413, NCT02610439
• Eastern Cooperative Oncology Group Operations Office
  U10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013
  Named on NCT00899418